- Home
- MANH vs PCVX Comparison
MANH vs PCVX Comparison
Compare MANH & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MANH | PCVX |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 8.6B |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MANH | PCVX |
|---|---|---|
| Price | $139.60 | $57.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $209.73 | $88.25 |
| AVG Volume (30 Days) | 753.5K | ★ 986.9K |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.56 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $131,300,000.00 | N/A |
| Revenue This Year | $8.10 | N/A |
| Revenue Next Year | $8.81 | N/A |
| P/E Ratio | $168.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $119.06 | $28.09 |
| 52 Week High | $247.22 | $65.00 |
Technical Indicators
Market Signals| Indicator | MANH | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 54.10 | 43.61 |
| Support Level | $136.61 | $52.04 |
| Resistance Level | $150.95 | $58.95 |
| Average True Range (ATR) | 5.53 | 2.05 |
| MACD | 1.20 | -0.61 |
| Stochastic Oscillator | 62.96 | 19.29 |
Price Performance
Historical ComparisonAbout MANH Manhattan Associates Inc.
Manhattan Associates provides software that helps users manage their supply chains, inventory, and omnichannel operations. Customers are generally retailers, wholesalers, manufacturers, and logistics providers. The company was founded in 1990 and serves more than 1,200 customers worldwide.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.